Nitrates in Angina Management

Introduction to Nitrates

Nitrates are essential vasodilators for both acute symptom relief and prophylaxis of angina, with different formulations requiring specific dosing intervals to prevent tolerance and maintain efficacy, as recommended by the European Society of Cardiology 1, 2

The American College of Cardiology recommends nitroglycerin (NTG) sublingual tablets: 0.3-0.6 mg (up to 1.5 mg), with effect duration of 1-7 minutes; should be dissolved under the tongue at first sign of angina attack 3
The American College of Cardiology also recommends NTG spray: 0.4 mg as needed, with similar duration to sublingual tablets 3
Isosorbide dinitrate (ISDN) oral dosing is 5-80 mg, 2-3 times daily (duration up to 8 hours), as suggested by the American College of Cardiology 3
Isosorbide mononitrate (ISMN) oral dosing is 20 mg twice daily (duration 12-24 hours), as recommended by the American College of Cardiology 3

Nitrates act as endothelium-independent vasodilators with both peripheral and coronary vascular effects, according to the American Heart Association 4
They primarily dilate capacitance vessels, decreasing cardiac preload and reducing ventricular wall tension, as stated by the American Heart Association 4

The American College of Cardiology recommends initiating intravenous nitroglycerin at 10 mcg/min via continuous infusion through non-absorbing tubing 5
The European Society of Cardiology suggests a daily nitrate-free interval of 10-12 hours to prevent tolerance 1, 2

The European Society of Cardiology notes that common side effects of nitrates include headache (dose-dependent) 2
The American Heart Association warns that nitrates may cause hypotension, especially postural 4
The American College of Cardiology advises that nitrates are contraindicated with phosphodiesterase inhibitors due to risk of profound hypotension, although this is not directly cited, a similar warning is given for patients with initial systolic BP <90 mmHg or ≥30 mmHg below baseline 5

The American College of Cardiology states that tolerance is dose and duration dependent, typically developing after 24 hours of continuous therapy 5, 3
The European Society of Cardiology recommends providing a daily "nitrate-free interval" of 10-12 hours to prevent tolerance 2

The European Society of Cardiology recommends short-acting nitrates for immediate relief of acute angina attacks 1, 2
The American College of Cardiology suggests that long-acting nitrates reduce frequency and severity of anginal attacks and may increase exercise tolerance 2
The American Heart Association recommends intravenous nitroglycerin for patients with heart failure, hypertension, or symptoms not relieved by sublingual nitroglycerin and beta-blockers 4

Continuous 24‑hour nitrate exposure eliminates anti‑anginal efficacy within 24 hours, and increasing the dose does not restore benefit【6】.
A mandatory nitrate‑free interval of 10–14 hours each day is required to prevent rapid tolerance development that would otherwise abolish all anti‑anginal effect【6】.

The American College of Cardiology recommends eccentric (asymmetric) dosing regimens that provide 12–14 hours of therapeutic coverage while preserving a 10–14 hour nitrate‑free interval to avoid tolerance【6】.

Administer doses at approximately 7 AM and 1 PM (instead of a symmetric 7 AM/7 PM schedule) to achieve 6–8 hours of coverage after each dose and a 14‑hour overnight nitrate‑free period【6】.
Use total daily doses ranging from 5 mg to 80 mg given two or three times per day on the asymmetric schedule【6】.

A slow‑release formulation of 60–240 mg taken once daily in the morning provides sustained daytime coverage while maintaining the nitrate‑free interval【6】.

Apply a patch delivering 0.2–0.8 mg/hour for 12 hours during daylight hours, then remove it for a 12‑hour nitrate‑free interval overnight【6】.

In the setting of unstable angina, continuous intravenous nitroglycerin is recommended despite the risk of tolerance, because rapid titration is essential for immediate symptom control【6】.
Tolerance can be temporarily overcome by escalating the IV infusion to 200–400 µg/min in the acute phase【6】.